Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

39.93 

0.72 1.8%

as of Mar 05 '21

52 Week Range:

20.03 50.26


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Equity (BVPS) 8.43
6.81
6.22
13.68
12.66
growth rate -19.2% -8.7% 119.9% -7.5%
Earnings BIT -3.68
-23.14
-65.34
-75.89
88.10
-149.00
-119.23
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Avg.PE -7.57
-10.64
27.43
27.43
growth rate 0.0% 100.0% 0.0%
ROA -231.43
-133.41
-21.17
-31.95
-39.40
26.92
-18.19
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
ROE -23.98
-33.27
-42.45
28.89
-19.76
growth rate 0.0% 0.0% 100.0% -100.0%
ROIC -23.96
-33.27
-42.45
25.97
-19.95
growth rate 0.0% 0.0% 100.0% -100.0%
Cur. Ratio 0.47
0.33
27.23
9.66
11.64
15.24
10.25
growth rate -29.8% 8,151.5% -64.5% 20.5% 30.9% -32.7%
Quick Ratio 0.47
0.33
26.80
9.37
11.17
14.81
9.93
growth rate -29.8% 8,021.2% -65.0% 19.2% 32.6% -33.0%
Leverage 1.02
1.07
1.09
1.07
1.11
growth rate 4.9% 1.9% -1.8% 3.7%
Balance Sheet Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Acct.Receivable 1.09
1.88
2.14
1.03
0.47
9.34
38.15
growth rate 73.0% 13.5% -51.7% -54.2% 1,874.0% 308.6%
Acct.Payable 4.65
0.33
1.01
1.54
4.83
4.41
6.41
10.62
growth rate -92.8% 203.6% 52.2% 213.2% -8.7% 45.3% 65.7%
Cur.Assets 2.21
3.03
118.15
93.37
168.00
337.91
345.03
531.20
growth rate 37.3% 3,798.0% -21.0% 79.9% 101.1% 2.1% 54.0%
Total Assets 2.51
3.49
221.38
172.73
198.68
543.81
497.91
708.16
growth rate 39.1% 6,241.5% -22.0% 15.0% 173.7% -8.4% 42.2%
Cash 1.12
1.12
54.12
24.84
46.66
75.56
69.51
338.43
growth rate 0.2% 4,727.5% -54.1% 87.8% 62.0% -8.0% 386.9%
Cur.Liabilities 4.65
9.19
4.34
9.67
14.44
22.18
33.68
81.45
growth rate 97.5% -52.8% 122.8% 49.3% 53.6% 51.9% 141.9%
Liabilities 4.65
9.19
4.57
11.00
15.65
34.97
47.71
330.41
growth rate 97.5% -50.2% 140.5% 42.3% 123.5% 36.5% 592.5%
LT Debt 5.85
growth rate
Equity -18.29
216.81
161.74
183.03
508.85
450.20
377.75
growth rate 100.0% -25.4% 13.2% 178.0% -11.5% -16.1%
Common Shares 13.00
13.00
9.00
26.00
30.00
37.00
37.00
growth rate 0.0% -30.8% 188.9% 15.4% 23.3% 0.0%
Cash Flow Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Capital Expenditures 0.52
0.52
8.15
7.16
13.28
11.72
growth rate 0.0% 1,461.1% -12.1% 85.5% -11.7%
Cash From OA -2.40
-22.52
-48.56
-57.99
104.65
-107.71
-54.06
growth rate 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
FCF per Share -0.70
-1.38
-2.58
2.43
-2.74
growth rate 0.0% 0.0% 100.0% -100.0%
Sale Purchase of Stock 1.97
0.00
145.29
0.18
84.60
204.44
8.38
200.21
growth rate -100.0% 14,529,000.0% -99.9% 47,161.5% 141.7% -95.9% 2,290.3%
FCF -3.00
-2.00
-23.00
-57.00
-65.00
91.00
-119.00
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Income Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20
Sales 6.09
6.12
7.59
4.59
10.39
218.51
35.23
154.57
growth rate 0.5% 24.0% -39.5% 126.5% 2,002.4% -83.9% 338.7%
Op.Income -5.39
-3.68
-23.14
-65.34
-75.89
88.10
-149.00
-119.23
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
IBT -5.39
-4.00
-22.81
-63.40
-73.17
104.12
-97.49
-106.01
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
Net Income -5.39
-4.00
-22.81
-62.97
-73.17
99.94
-94.73
-111.25
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%
EPS -0.44
-0.37
-2.59
-2.38
-2.45
2.73
-2.58
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0%
Gross Profit 5.76
0.15
-11.19
-41.85
-48.54
124.99
-97.19
growth rate -97.4% -100.0% 0.0% 0.0% 100.0% -100.0%
R&D 5.05
4.96
83.87
83.87
83.87
83.87
124.19
166.29
growth rate -1.8% 1,590.7% 0.0% 0.0% 0.0% 48.1% 33.9%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT -34.46
-40.32
-37.70
-41.83
13.95
growth rate 0.0% 0.0% 0.0% 100.0%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 19.18
38.15
44.52
42.88
122.12
growth rate 99.0% 16.7% -3.7% 184.8%
Acct.Payable 9.61
6.41
9.01
10.90
15.24
growth rate -33.3% 40.6% 21.0% 39.8%
Cur.Assets 360.23
345.03
338.23
329.08
386.95
growth rate -4.2% -2.0% -2.7% 17.6%
Total Assets 509.24
497.91
463.94
449.74
541.17
growth rate -2.2% -6.8% -3.1% 20.3%
Cash 79.59
69.51
69.41
94.22
93.22
growth rate -12.7% -0.2% 35.8% -1.1%
Inventory
growth rate
Cur.Liabilities 31.35
33.68
31.79
40.20
63.61
growth rate 7.4% -5.6% 26.5% 58.2%
Liabilities 40.84
47.71
43.78
51.88
125.51
growth rate 16.8% -8.2% 18.5% 142.0%
LT Debt
growth rate
Equity 468.40
450.20
420.15
397.86
415.66
growth rate -3.9% -6.7% -5.3% 4.5%
Common Shares 37.00
0.00
0.00
0.00
0.00
growth rate -100.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 2.68
1.03
4.63
3.28
6.07
growth rate -61.5% 349.1% -29.2% 85.2%
Cash Dividends
growth rate
Cash From OA -29.15
-25.51
-35.57
-21.50
-36.46
growth rate 0.0% 0.0% 0.0% 0.0%
Sale Purchase of Stock 1.33
1.55
2.76
1.83
1.46
growth rate 16.2% 78.2% -33.9% -20.0%
FCF -31.83
-26.54
-40.20
-24.77
-42.53
growth rate 0.0% 0.0% 0.0% 0.0%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 14.70
11.77
17.64
16.57
98.91
growth rate -20.0% 49.9% -6.1% 497.1%
Op.Income -35.90
-40.32
-37.70
-41.83
13.95
growth rate 0.0% 0.0% 0.0% 100.0%
IBT -34.75
-28.86
-40.04
-34.26
8.79
growth rate 0.0% 0.0% 0.0% 100.0%
Net Income -34.58
-26.46
-40.04
-33.76
8.79
growth rate 0.0% 0.0% 0.0% 100.0%
Gross Profit 12.21
-25.83
-22.80
-26.23
81.55
growth rate -100.0% 0.0% 0.0% 100.0%
R&D 35.69
43.97
43.97
43.97
43.97
growth rate 23.2% 0.0% 0.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (6.07)

YOY Growth Grade:

F (3.00)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 27.43 16.88 -15.79
EPS / Growth 0.0% 2.37 -2.2%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 22.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 0.0% 7.7% 7.7%
Future PE 0.00 14.29 14.29
Future EPS 2.37 4.97 4.97
Value Price
MOS %
0.00
-100.0%
17.56
-56.0%
17.56
-56.0%
MOS Price 0.00 8.78 8.78
IRT 16.88 10.66 10.66

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.